-
Lourdes has been an important Catholic pilgrimage site for the elderly and infirm since 1858. This year marks the 150th anniversary of the apparition known as the "Lady of Lourdes," which was observed on multiple occasions that year by a 14-year-old peasant girl out searching for firewood.
-
-
Single nucleotide polymorphisms were examined within TLR2, TLR3, TLR4, and TLR9 in a population of 336 HSCT recipients and their unrelated donors. Using multivariate Cox regression analysis, two donor TLR4 haplotypes were found to be associated with increased risk of developing invasive aspergillosis in the HSCT recipients.
-
In the issue: 5-á reductase inhibitors and hip fracture in men; the effects of drug-reimbursement policy on outcomes; new guidelines for type 2 diabetes; beta-blocker-associated brady-cardia is linked to CVD events; FDA Updates.
-
-
The dramatic reduction in in-stent restenosis (ISR) afforded by drug-eluting stents (DES) led to their widespread use throughout the world. Subsequently, more patients and lesions could be treated percutaneously with less thought about ISR. With the advent of a more widespread adoption of percutaneous coronary intervention, registry data began suggesting an increased risk of late and very late stent thrombosis with DES compared to bare-metal stents (BMS).
-
The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevenzione trial demonstrated a lower mortality rate in post myocardial infarction patients treated with n-3 polyunsaturated fatty acids (PUFA) vs controls, which was mainly due to a reduction in sudden death.
-
In this paper, Adabag et al from the Mayo Clinic analyzed the risk of sudden death after an acute myocardial infarction over a 28-year period in patients residing in Olmsted County, MN.
-
-
Prasugrel, a novel third-generation oral thienopyridine (following ticlopidine and clopidogrel), has recently been shown to provide clinically important platelet inhibition in acute coronary syndromes (ACS), with decreased ischemic events compared to clopidogrel in the TRITON-TIMI 38 trial of almost 14,000 ACS patients undergoing PCI.
